ClinicalTrials.gg
RecruitingNCT07223047Updated May 28, 2026

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

A Phase 1/2 interventional study of BMS-986523 and Gemcitabine in Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Bristol-Myers Squibb. Recruiting at 8 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
252
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb — 21 open to participants now, 35 under way, 10 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bristol-Myers Squibb.

Planned enrollment
41st of 107
252 · median 169
Started
2025
with 9 others
Phase 1/2
19 of 131
5 open now
Primary completion
2028-10
later than 20 of 34 live
Registered
121st of 131
by date

Among the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, this one is the 41st largest by planned enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2025, is one of 19 in phase 1/2, reaches primary completion later than 20 of the 34 other live ones, and was the 121st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

21 of the 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Carcinoma, Non-Small-Cell Lung by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies

03

Conditions studied

  • Advanced Solid Malignancies
  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)

Keywords

  • Non-small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer (CRC)
  • Pancreatic Ductal Adenocarcinoma (PDAC)
  • Pancreatic Cancer
  • Lung Cancer
  • Kirsten rat sarcoma viral oncogene homolog (KRAS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a confirmed diagnosis of a locally advanced and unresectable or solid tumor with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification).
  • Participants must, for Arm D, have a expression (≥50%).
  • Participants must have previously received, be ineligible for, or decline (after having been provided adequate information to make an informed decision) the protocol defined standard of care (SoC) treatments.

Exclusion criteria

Exclusion Criteria

  • Participants must not have untreated central nervous system (CNS) .
  • Participants must not have concurrent (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
  • Participants must not have a history of, or any evidence of, interstitial lung disease or active, non-infectious pneumonitis. A history of radiation pneumonitis in the radiation field is permitted.
  • Participants must not have a history of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: BMS-986523

  • Experimental
    Arm B

    Drug: BMS-986523

  • Experimental
    Arm C

    Drug: BMS-986523

  • Experimental
    Arm D

    Drug: BMS-986523 · Drug: Pembrolizumab

  • Experimental
    Arm E

    Drug: BMS-986523 · Drug: Cetuximab

  • Experimental
    Arm F

    Drug: BMS-986523 · Drug: Gemcitabine · Drug: Nab-Paclitaxel

Interventions

  • DrugBMS-986523

    Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

  • Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to 3 years

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to 3 years

  3. Number of participants with AEs meeting protocol-defined dose limiting toxicity (DLT) criteria

    Time frame: Up to 3 years

  4. Number of participants with AEs leading to discontinuation

    Time frame: Up to 3 years

  5. Number of deaths

    Time frame: Up to 3 years

Secondary outcomes

  1. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the investigator.

    Time frame: Up to 3 years

  2. Duration of response (DOR) per RECIST v1.1 as assessed by the investigator.

    Time frame: Up to 3 years

  3. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 3 years

  4. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 3 years

  5. Area under the concentration-time curve in 1 dosing interval (AUC(TAU))

    Time frame: Up to 3 years

07

Study locations

6 of 8 sites recruiting
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
    Recruiting
    • Nilofer Azad, Site 0009 · Contact410-502-2995
  • NEXT Oncology
    San Antonio, Texas 78229, United States
    Recruiting
    • David Sommerhalder, Site 0001 · Contact210-580-9500
  • START Mountain Region
    West Valley City, Utah 84119, United States
    Recruiting
    • Justin Call, Site 0007 · Contact801-907-4750
  • NEXT Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alexander Spira, Site 0011 · Contact703-280-5390
  • BC Cancer Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
    Recruiting
    • Daniel Renouf, Site 0002 · Contact6048776000Ext3297
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
    • Albiruni Abdul Razak, Site 0010 · Contact6479709845
  • Local Institution - 0006
    Badalona, Barcelona [Barcelona] 08916, Spain
    Not yet recruiting
    • Site 0006 · Contact
  • Local Institution - 0008
    Hortaleza, Madrid 28050, Spain
    Not yet recruiting
    • Site 0008 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2028, 34 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 34 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Oct 13, 2028
CompletionEst.
Oct 13, 2028
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07223047
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Nov 25, 2025
Primary completion
Oct 13, 2028 (estimated)
Completion
Oct 13, 2028 (estimated)
Last update
May 28, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion